BRPI1012890A2 - composição adjuvante aquosa, composição imunogênica, processo para preparar uma composição imunogênica, e, kit - Google Patents

composição adjuvante aquosa, composição imunogênica, processo para preparar uma composição imunogênica, e, kit

Info

Publication number
BRPI1012890A2
BRPI1012890A2 BRPI1012890A BRPI1012890A BRPI1012890A2 BR PI1012890 A2 BRPI1012890 A2 BR PI1012890A2 BR PI1012890 A BRPI1012890 A BR PI1012890A BR PI1012890 A BRPI1012890 A BR PI1012890A BR PI1012890 A2 BRPI1012890 A2 BR PI1012890A2
Authority
BR
Brazil
Prior art keywords
composition
immunogenic composition
kit
preparing
aqueous adjuvant
Prior art date
Application number
BRPI1012890A
Other languages
English (en)
Inventor
Ingrid Lemoine Dominique
Henderickx Veronique
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40937237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1012890(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of BRPI1012890A2 publication Critical patent/BRPI1012890A2/pt
Publication of BRPI1012890B1 publication Critical patent/BRPI1012890B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI1012890-5A 2009-06-10 2010-06-08 Composição adjuvante aquosa, composição imunogênica, processo para preparar uma composição imunogênica, e, kit BRPI1012890B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0910046.2 2009-06-10
GBGB0910046.2A GB0910046D0 (en) 2009-06-10 2009-06-10 Novel compositions
PCT/EP2010/058017 WO2010142685A1 (en) 2009-06-10 2010-06-08 Adjuvant compositions comprising a non-ionic isotonicity agent

Publications (2)

Publication Number Publication Date
BRPI1012890A2 true BRPI1012890A2 (pt) 2018-02-27
BRPI1012890B1 BRPI1012890B1 (pt) 2022-03-22

Family

ID=40937237

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1012890-5A BRPI1012890B1 (pt) 2009-06-10 2010-06-08 Composição adjuvante aquosa, composição imunogênica, processo para preparar uma composição imunogênica, e, kit

Country Status (31)

Country Link
US (2) US20120087976A1 (pt)
EP (1) EP2440242B1 (pt)
JP (3) JP5647677B2 (pt)
KR (1) KR101473686B1 (pt)
CN (2) CN102458457B (pt)
AU (1) AU2010257538B2 (pt)
BR (1) BRPI1012890B1 (pt)
CA (1) CA2764421C (pt)
CL (1) CL2011003113A1 (pt)
CO (1) CO6440528A2 (pt)
CY (1) CY1115522T1 (pt)
DK (1) DK2440242T3 (pt)
DO (1) DOP2011000346A (pt)
EA (1) EA024074B1 (pt)
ES (1) ES2494442T3 (pt)
GB (1) GB0910046D0 (pt)
HR (1) HRP20140792T1 (pt)
IL (1) IL216231A0 (pt)
MA (1) MA33412B1 (pt)
MX (1) MX2011013162A (pt)
MY (1) MY159819A (pt)
NZ (1) NZ596503A (pt)
PE (1) PE20120319A1 (pt)
PL (1) PL2440242T3 (pt)
PT (1) PT2440242E (pt)
RS (1) RS53550B1 (pt)
SG (1) SG176638A1 (pt)
SI (1) SI2440242T1 (pt)
SM (1) SMT201400134B (pt)
UA (1) UA104888C2 (pt)
WO (1) WO2010142685A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2975024T3 (pl) 2009-06-10 2018-09-28 Chugai Seiyaku Kabushiki Kaisha Związki tetracykliczne
BR112013003879B1 (pt) 2010-08-20 2020-12-22 Chugai Seiyaku Kabushiki Kaisha composição compreendendo compostos tetracíclicos e formulação oralmente administrável que a compreende
CA2819297A1 (en) * 2010-12-14 2012-06-21 Glaxosmithkline Biologicals S.A. Mycobacterium antigenic composition
TR201815994T4 (tr) 2012-09-25 2018-11-21 Chugai Pharmaceutical Co Ltd Ret inhibitörü.
KR102242875B1 (ko) * 2014-03-25 2021-04-20 더 가번먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 리프리젠티드 바이 더 세크리터리 오브 더 아미 모노포스포릴 지질 a (mpla)-함유 리포솜 조성물 및 사포닌을 포함하는 무독성 아주반트 제제
CN106458967A (zh) 2014-04-25 2017-02-22 中外制药株式会社 四环化合物的新结晶
CN106456651A (zh) 2014-04-25 2017-02-22 中外制药株式会社 以高用量含有四环性化合物的制剂
TWI718102B (zh) 2014-08-08 2021-02-11 日商中外製藥股份有限公司 ４環性化合物的非晶質體
US11077093B2 (en) 2015-01-16 2021-08-03 Chugai Seiyaku Kabushiki Kaisha Combination drug
SG10202012205XA (en) 2015-11-06 2021-01-28 Adjuvance Technologies Inc Triterpene saponin analogues
CA3045952A1 (en) * 2016-12-07 2018-06-14 Glaxosmithkline Biologicals Sa Novel process
IL292991A (en) 2017-04-25 2022-07-01 Adjuvance Tech Inc Triterpene saponin analogs
JP2020521781A (ja) 2017-05-30 2020-07-27 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム リポソームに内包されたｒｎａを製造する方法
AU2018350887A1 (en) * 2017-10-16 2020-03-05 Adjuvance Technologies, Inc. Triterpene saponin analogues
EP3717005A1 (en) 2017-12-01 2020-10-07 GlaxoSmithKline Biologicals S.A. Saponin extraction
JP2021504424A (ja) 2017-12-01 2021-02-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
EP3815688B1 (en) 2018-06-29 2023-12-06 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing poorly-soluble basic medicine
AU2019337018B2 (en) 2018-09-04 2024-03-07 Chugai Seiyaku Kabushiki Kaisha Method of producing tetracyclic compound
WO2020109365A1 (en) 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
BR112021024363A2 (pt) 2019-06-05 2022-03-22 Glaxosmithkline Biologicals Sa Purificação de saponina
JP2022543264A (ja) * 2019-08-05 2022-10-11 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム プロテインｄポリペプチドを含む組成物を調製するプロセス
EP4021407A1 (en) 2019-08-30 2022-07-06 GlaxoSmithKline Biologicals S.A. Jet mixing lipid nanoparticle manufacturing process
EP4570269A4 (en) * 2023-03-15 2025-10-22 United Immunity Co Ltd LIPID PARTICLE
WO2025180443A1 (en) * 2024-02-29 2025-09-04 Immunadd Inc. Adjuvant composition, pharmaceutical composition comprising the same, and method for preventing or treating disease caused by viral infection, bacterial infection, protozoal infection or cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
EP0689454B2 (en) * 1993-03-23 2005-02-23 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
TR200002284T2 (tr) 1998-02-05 2000-11-21 Smithkline Beecham Biologicals S.A. Mage ailesinden tümör ile ilgili tümör türevleri
DK1075276T3 (da) * 1998-05-07 2008-02-11 Corixa Corp Adjuvanssammensætning og fremgangsmåder til dens anvendelse
JP3765232B2 (ja) 2000-11-16 2006-04-12 株式会社ジェイテクト 電動式パワーステアリング装置及びこれに用いる歯車の製造方法
GB0409940D0 (en) 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
GB0411411D0 (en) * 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
EP1829887B1 (en) * 2004-11-29 2011-08-24 Changchun Huapu Biotechnology Co., Ltd. Cpg single-strand deoxynucleotides for use as adjuvant
US9486515B2 (en) * 2005-06-27 2016-11-08 Glaxosmithkline Biologicals S.A. Immunogenic composition
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
DK2114993T3 (da) 2007-01-15 2012-10-22 Glaxosmithkline Biolog Sa Vaccine
MX2009007572A (es) 2007-01-15 2009-10-13 Glaxosmithkline Biolog Sa Proteinas de fusion que contienen los antigenos de rechazo de tumor ny-eso-1 y.
CA2687632C (en) * 2007-05-24 2013-01-15 Glaxosmithkline Biologicals S.A. Lyophilised antigen composition
GB0910045D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions

Also Published As

Publication number Publication date
AU2010257538A1 (en) 2011-12-08
EP2440242B1 (en) 2014-06-25
HRP20140792T1 (hr) 2014-10-10
WO2010142685A1 (en) 2010-12-16
PL2440242T3 (pl) 2014-11-28
MA33412B1 (fr) 2012-07-03
UA104888C2 (uk) 2014-03-25
KR101473686B1 (ko) 2014-12-18
RS53550B1 (sr) 2015-02-27
KR20120031497A (ko) 2012-04-03
PT2440242E (pt) 2014-08-29
DK2440242T3 (da) 2014-09-01
CO6440528A2 (es) 2012-05-15
AU2010257538B2 (en) 2016-10-20
CN104367997B (zh) 2019-01-22
CA2764421A1 (en) 2010-12-16
MY159819A (en) 2017-02-15
CL2011003113A1 (es) 2012-08-31
CY1115522T1 (el) 2017-01-04
CN102458457B (zh) 2015-05-20
JP2015042646A (ja) 2015-03-05
EP2440242A1 (en) 2012-04-18
CN104367997A (zh) 2015-02-25
EA201190286A1 (ru) 2012-06-29
CA2764421C (en) 2016-12-06
NZ596503A (en) 2013-08-30
JP5977789B2 (ja) 2016-08-24
EA024074B1 (ru) 2016-08-31
GB0910046D0 (en) 2009-07-22
SG176638A1 (en) 2012-01-30
BRPI1012890B1 (pt) 2022-03-22
DOP2011000346A (es) 2012-01-15
ES2494442T3 (es) 2014-09-15
MX2011013162A (es) 2012-01-30
JP2016193912A (ja) 2016-11-17
IL216231A0 (en) 2012-01-31
PE20120319A1 (es) 2012-04-16
JP5647677B2 (ja) 2015-01-07
US20120087976A1 (en) 2012-04-12
CN102458457A (zh) 2012-05-16
JP6261647B2 (ja) 2018-01-17
JP2012529464A (ja) 2012-11-22
US20180021417A1 (en) 2018-01-25
SI2440242T1 (sl) 2014-09-30
SMT201400134B (it) 2014-11-10

Similar Documents

Publication Publication Date Title
BRPI1012890A2 (pt) composição adjuvante aquosa, composição imunogênica, processo para preparar uma composição imunogênica, e, kit
BRPI0916884A2 (pt) composição imunogênica, processo para preparar uma composição imunogênica, uso de uma composição imunogênica, e, kit
BR112013014598A2 (pt) composição imunogênica, uso de uma composição imunogênica, processo para preparar uma composição imunogênica, método para a fabricação de uma composição imunogênica estável, e, kit
BRPI1010775A2 (pt) composição, método para preparar uma composição, e, uso de uma composição.
BRPI0909820A2 (pt) Processo para estabilização de composição de vacina contra gripe, para estabilização de composição de vacina contendo adjuvante e para preparação de vacina, composições de vacina, kit de vacina e método de estocagem de uma matéria prima
BRPI1006141A2 (pt) composições de anticorpo modificado, métodos para preparar e usar as mesmas
BRPI0918349A2 (pt) Processo para preparar dióxido de divinilareno
BRPI0912384A2 (pt) composição, e, método para preparar uma composição
BRPI1013051A2 (pt) composição imunogênica, uso de uma composição imunogênica, processo para fazer uma composição imunogênica, e, kit.
BRPI0813307A2 (pt) Composição imunogênica, vacina, e, processo para fabricar a vacina
BR112012004807A2 (pt) vacina para pcsk9
BRPI0924622A2 (pt) composições para tratamento de tecidos, processo de fabricação, e método de uso.
BRPI1014606A2 (pt) Maltotriosil transferase, processo para produção e uso da mesma
BRPI1013561A2 (pt) Processo para a preparação de alogliptina
BRPI0921399A2 (pt) composição de graxa lubrificante, processo para preparar composição lubrificante, e, uso de uma composição de graxa lubrificante
BRPI0911815A2 (pt) estrutura de multifilme, estrutura de envelope feita de uma estrutura de multifilme, uso de uma estrutura de multifilme e processo para preparar uma estrutura de multifilme
BRPI1010617A2 (pt) uso de uma composição, composição, uso não médico da composição, e, método para preprar uma composição.
BRPI0922984A2 (pt) processo para preparar trietanolamina pura
BR112012001998A2 (pt) solução oftálmica, uso de um composto, e, método para preparação de uma solução oftálmica.
BRPI1005919A2 (pt) composição imunogênica
BRPI1011639A2 (pt) composição anticongelante, e, método para aumentar a estabilidade térmica de uma composição anticongelante
BRPI1008484A2 (pt) codificador, decodificador e método para os mesmos
BR112013012873A2 (pt) processo para preparar uma n, n-dialquiletanolamina
BRPI1008987A2 (pt) processo para preparar 3,3,3-trifluoropropeno
BR112012008202A2 (pt) processo de preparação de uma composição, componentes e uso da composição

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/06/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.